| Followers | 826 |
| Posts | 119569 |
| Boards Moderated | 14 |
| Alias Born | 09/05/2002 |
Friday, January 28, 2011 1:24:01 PM
How does Gilenya affect Copaxone?
According to NVS’ 4Q10 CC, approximately half of Gilenya’s US sales are coming from patients who were not using any MS drugs. Of the other half—i.e. patients who were on another MS drug and switched to Gilenya—25-30% are switching from Copaxone. Thus, each patient start on Gilenya is subtracting 0.125-0.15 patients from the number taking Copaxone.
This graphic comes from NVS’ 4Q10 CC:
Source: http://www.novartis.com/downloads/investors/sales-results/novartis-investor-presentation-fresco-january-27-2011.pdf
According to NVS’ 4Q10 CC, approximately half of Gilenya’s US sales are coming from patients who were not using any MS drugs. Of the other half—i.e. patients who were on another MS drug and switched to Gilenya—25-30% are switching from Copaxone. Thus, each patient start on Gilenya is subtracting 0.125-0.15 patients from the number taking Copaxone.
This graphic comes from NVS’ 4Q10 CC:
Source: http://www.novartis.com/downloads/investors/sales-results/novartis-investor-presentation-fresco-january-27-2011.pdf
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
